Kymriah™(tisagenlecleucel) in children and young adults with B-cell ALL that is refractory or relapsed at least twice


Kymriah (pronounced: Kim-RYE-ah) is the first FDA-approved CAR-T cell therapy available in the US

Usage Rights & Restrictions

This media asset is free for editorial broadcast, print, online and radio use. It is restricted for other purposes.